Menu
Menu
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, today announced an expanded collaboration with Result Laboratorium, a leading clinical laboratory in the Netherlands, to advance the delivery of pharmacogenomics (PGx) insights across the region using the SOPHiA DDM™ Platform and SOPHiA DDM™ Dispatch.
By centralizing sequencing and analysis at Result Laboratorium, SOPHiA DDM™ Dispatch allows healthcare institutions, regardless of their in-house expertise or infrastructure, to offer high-quality PGx insights. Samples can be sent to Result Laboratorium, where sequencing and analysis take place leveraging SOPHiA DDM™ Platform and PGx applications. This empowers collaboration where each institution can focus on its own strengths, whether that’s patient care, sample collection, or regional expertise, while leveraging the secure and cloud-native SOPHiA DDM™ Platform.
Built on over a decade of innovation, the SOPHiA DDM™ Platform is designed to meet the stringent data safety requirements of modern healthcare. The Platform operates in a fully GDPR-compliant, HIPAA-compliant, and cloud-native environment. With certifications that include ISO 27001:2022, ISO 27017:2015, and ISO 27018:2019, as well as Cloud Computing Compliance Controls Catalogue (C5) attestation in Germany. These credentials demonstrate a strong commitment to the highest standards of information security, privacy, and cloud trust.
“With this model, Result Laboratorium can act as a regional hub, empowering other institutions to scale PGx analysis without the burden of building complex infrastructure,” said Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICS. “It’s a powerful example how we can unite strengths across institutions, enabling more personalized care through a shared, secure, and scalable data ecosystem.”
“We’re proud to take a leadership role in making pharmacogenomics more accessible,” said Robert Akkers, Molecular Biologist at Result Laboratorium. “The SOPHiA DDM™ Platform gives us the analytical depth, scalability, and compliance we need to deliver high-quality insights—both for our own institution and for labs across the region looking to offer PGx without building from scratch.”
SOPHiA GENETICS’ approach to centralized data generation paired with decentralized collaboration helps ensure consistent, high-quality insights while reducing duplication of effort across labs. Participating institutions retain control over their clinical workflows and relationships, while benefiting from the global infrastructure and analytical rigor that SOPHiA GENETICS has built over the last decade.
To learn more about SOPHiA DDM™ Dispatch and how it supports scalable, decentralized genomics, visit sophiastg.wpenginepowered.com or connect with SOPHiA GENETICS on LinkedIn. For more on Result Laboratorium, visit www.resultlaboratorium.nl or follow their updates on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
